课题基金 / 基金详情

Human Leukemia Growth Inhibition by a Novel Retinoid

Human Leukemia Growth Inhibition by a Novel Retinoid
新型类维生素A抑制人类白血病生长
批准号:
7087066
负责人:
JOSEPH A FONTANA
金额:
$45.85万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-07-01 至 2009-04-30

项目摘要

项目成果

JOSEPH A FONTANA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN/CD437) belongs to a class of adamantyl retinoids (AR) that induce apoptosis through as yet undefined mechanism(s). We have now identified an AHPN analog 4-[3-(1-adamanyly)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-CI-AHPC), which binds to, but does not activate, the retinoic acid nuclear receptors. 3-C1-AHPC displays decreased toxicity compared to AHPN but continues to display high efficacy in inhibiting human acute myelogenous leukemia (AML) cell growth in vitro and mouse AML cells in vivo. In addition, we have found that 3-C1-AHPC induces the expression of a novel protein termed CARP-1. We recently identified CARP-1 as an important regulator of apoptosis by the ARs. Hypothesis: In this proposal we hypothesize that 3-C1-AHPC and newly synthesized analogs are highly active in inhibiting the growth of human primary AML cells in NOD-SCID mice and thus represent potential therapeutic agents in the treatment of AML. In addition, we also hypothesize that 3-CL-AHPC/analog apoptosis signaling is through its activation of the important transcriptional regulator, NFkB, and CARP-l-mediated pathways. Our hypothesis is based on the following observations. 1) 3-CI-AHPC inhibits the growth of AML cells in a syngeneic mouse model, patient derived AML cells, and human AML cell lines. 2) Inhibition of NFkB activation or inhibition of CARP-1 expression blocks 3-C1-AHPC-mediated apoptosis. We will confirm our hypothesis by conducting the following specific aims. Aim 1: Synthesize new analogs of 3-C1-AHPC. Aim 2: Demonstrate that 3-C1-AHPC and its analogs inhibit in vivo growth of human primary AML cells in NOD-SCID mice and display reduced toxicity. Aim 3: Delineate the mechanism(s) by which 3-CI-AHPC enhances CARP-1 expression and CARP-l-dependent reduced topoisomerase lIa levels. Aim 4: Delineate the pathway by which 3-C1-AHPC activates NFkB and its role in apoptosis induction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Human Leukemia Growth Inhibition by a Novel Retinoid
  • 批准号:
    7237940
  • 项目类别:
  • 资助金额:
    $45.86万
  • 财政年份:
    2004
  • 负责人:
    JOSEPH A FONTANA
  • 依托单位:
Human Leukemia Growth Inhibition by a Novel Retinoid
  • 批准号:
    6815356
  • 项目类别:
  • 资助金额:
    $47.22万
  • 财政年份:
    2004
  • 负责人:
    JOSEPH A FONTANA
  • 依托单位:
Human Leukemia Growth Inhibition by a Novel Retinoid
  • 批准号:
    7409181
  • 项目类别:
  • 资助金额:
    $46.31万
  • 财政年份:
    2004
  • 负责人:
    JOSEPH A FONTANA
  • 依托单位:
Human Leukemia Growth Inhibition by a Novel Retinoid
  • 批准号:
    6914222
  • 项目类别:
  • 资助金额:
    $45.59万
  • 财政年份:
    2004
  • 负责人:
    JOSEPH A FONTANA
  • 依托单位:
海外基金